Tadalafil Troche

Overview of Tadalafil Troche

Dosage Strength

20 mg

General Information

Similar to sildenafil and vardenafil, tadalafil is a type 5 selective PDE inhibitor. It is given orally to treat male erectile dysfunction (ED), pulmonary arterial hypertension (PAH), benign prostatic hypertrophy (BPH), or to treat both ED and BPH simultaneously. Unlike several impotence medications, tadalafil does not suppress prostaglandins (e.g., alprostadil). Tadalafil, which is more selective for PDE5 than for PDE6 found in the retina, has not been associated with visual abnormalities, in contrast to sildenafil. Tadalafil appears to have a longer half-life of effect than sildenafil and vardenafil for the treatment of ED (up to 36 hours). Tadalafil’s longer duration of action permits more spontaneity in sexual engagement because PDE inhibitors only induce erection when sexual stimulation is present. Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitor) are the first-line treatment for ED, according to therapeutic recommendations. 1 Phase II clinical trials for the treatment of female erectile dysfunction with tadalafil were terminated. Male erectile dysfunction (ED) was given FDA approval in November 2003, and in January 2008, approval for once-daily usage without consideration to timing of sexual activity was given. In May 2009, the FDA granted approval for the use of tadalafil (Adcirca) to treat pulmonary arterial hypertension (PAH). Patients receiving tadalafil had better exercise tolerance and less clinical deterioration compared to placebo in clinical tests of people with pulmonary arterial hypertension (PAH). Tadalafil was given FDA approval in October 2011 to treat both erectile dysfunction and benign prostatic hyperplasia (BPH), as well as its symptoms and signs.

References

1.Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2.Cialis (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2011 Oct.
3.Adcirca (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2011 Apr.
4.Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin N Am 2007;34:631-642.
5.Bortolotti M, Mari C, Giovannini M, et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci 2001;46:2301-2306.
6.Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Tadalafil) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2-9.
7.Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005;25:9-13.
8.Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol 2005;123(3):399-400.
9.Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005;123(3):400-1.
10.Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye 2005;19(6):715-7.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.

Get Started For $99 Initial Provider Consult